secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001213900-24-026871
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra plans reproxalap NDA resubmission for dry eye disease in H2 2024
------------------------------------------------------------------------

- Dry eye chamber trial to start H1 2024; NDA resubmission expected H2 2024 if positive.
- FDA review period expected to be six months for potential resubmission.
- Cash $142.8M as of Dec 31, 2023; projected to fund operations beyond 2026.
- Primary endpoint: ocular discomfort; trial design from four prior reproxalap chamber trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/0001213900-24-026871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024026871/ea0202743-8k_aldey.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-026871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer